Search Results
Pan-heme CAR: Anti-CD38 CAR T cells for myeloid, lymphoid and plasma cell malignancies
Our SCOR team has a razor-sharp focus on an exciting new treatment modality for blood cancers: chimeric antigen receptor (CAR) T cells. T cells can be trained to target cancer cells by genetic modification. In fact, previous support from the Leukemia & Lymphoma Society allowed us to successfully develop CAR T cells targeted to CD19, a pan-B cell marker.Development of BET protein bromodomain inhibitors for the treatment of patients with hematologic malignancies
In July 2012, LLS began its partnership with Constellation to support three first-in-human Phase 1 clinical trials for blood cancer patients and the partnership led to the ongoing trial "A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients."Targeting the inflammatory GM-CSF pathway in high risk CMML
Chronic myelomonocytic leukemia (CMML) is a rare but poorly understood blood cancer often presenting with crippling inflammatory symptoms that frequently evolves into acute leukemia. In an ongoing clinical trial, we have compelling molecular and clinical data that this disease responds effectively to blockade of GM-CSF with lenzulimab, a well-tolerated and safe antibody, in combination with azacitidine.REACH: Recruitment Expansion through community Access to Clinical trials in Hematologic malignancies
Mayo Clinic Rochester (MCR) is a tertiary center with 35,000 blood cancer visits annually. Circa 70% of patients referred to MCR come from 5 states: MN, WI, IA, SD and ND inhabited by 10,483,946 people living primarily in a rural setting. To improve local care access, MCR has developed the Mayo Clinic Health System (MCHS), a network of 17 community sites of which 7 have oncology care. In 2018, the MCR joined with the University of Minnesota to establish the Minnesota Cancer Clinical Trials Network (MCCTN) that includes 18 sites.A phase 2 expansion study of ICT01, an anti-BTN3A monoclonal antibody, in combination with azacitidine and venetoclax in patients with AML
In June 2022, LLS made an equity investment in ImCheck Therapeutics to "Support Clinical Development of the ICT01 Program for Blood Cancer Indications." ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
Peer-to-Peer Support
Patti Robinson Kaufmann First Connection® ProgramIf you or a family member has been diagnosed with a blood cancer, you may find it helpful to speak with someone who has gone through a similar experience and learned how to manage the same disease you're trying to cope with each day. The Patti Robinson Kaufmann First Connection® Program is a free service of The Leukemia & Lymphoma Society (LLS) that introduces patients and their loved ones to a trained peer volunteer who has gone through a similar experience.
Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma
Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.Enhancing the “fitness” of anti-BCMA CAR T cells for improved efficacy in multiple myeloma
Chimeric antigen receptor (CAR) T cell therapy is a form of immune-based therapy where a patient’s own immune cells are genetically engineered to recognize and kill the tumor cells. This therapy has revolutionized the treatment of certain blood cancers and excitingly, two CAR T cell products were recently approved for the treatment of multiple myeloma.A phase 1 study of CB-012, a CRISPR-edited allogeneic CAR-T targeting CLL1, in patients with acute myeloid leukemia
In February 2021, LLS made an equity investment in Caribou Biosciences to "Support allogeneic CD371 (CLL-1) CAR development for acute myeloid leukemia." Caribou is a clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.
Caregiver Support
Am I A Caregiver?If you’re providing regular assistance, you are a caregiver. Your loved one may only need support occasionally, or your loved one may need constant care. The kind of support needed will be different for each person and may also change over time. But if you're consistently providing care, you are a caregiver.
Here are just a few examples of caregiver tasks:
Treatment
Which side effects do I need to call my doctor about? Side effects of treatment are usually discussed with patients before the treatment is started. From the doctor's perspective, the side effects of greatest concern may be fever, breathing difficulties, hives or rashes, rapid heartbeat, confusion, and redness or pain at the IV site. From the patient's perspective, any side effect causing discomfort or limiting usual activity, such as diarrhea or nausea, is a concern. Report any side effects when they first appear.
A phase 1 study of CB-010, a CRISPR-edited allogeneic CAR-T targeting CD19, in patients with B-cell NHL
In February 2021, LLS made an equity investment in Caribou Biosciences to support "A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma." Caribou is a leading clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.A phase 1 study of CB-011, a CRISPR-edited allogeneic CAR-T targeting BCMA, in patients with multiple myeloma
In February 2021, LLS made an equity investment in Caribou Biosciences to support "A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma." Caribou is a leading clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.Who We Are
The Leukemia & Lymphoma Society is at the forefront of the fight to cure cancer. We are the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, we’ve invested nearly $1.3 billion in groundbreaking research, pioneering many of today’s most innovative approaches.
Cancer is a heck of an opponent.
It's a bully. But we aren't afraid of a fight. It's elusive. But our focus never fades. It's deadly. But we are known, cancer killers.
LLS Research Spotlight
This is your connection to the latest in LLS Research. LLS-funded researchers are making strides toward new therapies and pathways to cures for blood cancers. We're highlighting some of these researchers with detailed summaries of their latest publications and success stories, designed to give you an idea of the latest happenings in blood cancer research.
Subaru Loves to Care
The Leukemia & Lymphoma Society (LLS) is partnering with Subaru and its retailers to spread hope, love, and warmth to blood cancer patients and their families for the sixth consecutive year. As part of Subaru Loves to Care, we’re providing information on free education and support services from LLS to those fighting blood cancers across the country.
Marisa
Throughout my father’s journey, I was impressed by his care team, the advanced medicine used to treat blood cancer today, the individuals I met, people’s generosity, and the organizations I was introduced to. This journey opened my eyes to various organizations such as Be the Match and The Leukemia & Lymphoma Society (LLS).
LLS Researchers
Partnering for Cures – Our Unique Collaborations Span Continents
Cathy
I had blood cancer and for that, I’m lucky. I’m not being facetious, I really believe I’m lucky. The doctors told me that Stage 2 Hodgkin lymphoma (HL) is highly treatable and this is the cancer to have if you’re going to get cancer. But that’s not the only reason why I’m lucky. The very first philanthropic effort that I did with my BFF was when we were 17 years old and allowed to donate blood. This is one of the first times I realized I was lucky. By giving blood I could give the gift of life. It’s something I also had in common with my husband who is an avid blood donor.
Jack
On October 19, 2018, after complaining about excruciating pain in his back, we took our 16-year-old son Jack to see the pediatrician. The doctor checked him out and told us to immediately get him to the Children's Hospital of Colorado and go to the 7th floor to see Dr. Maloney. Not paying attention and thinking nothing was wrong, we didn't notice that the 7th floor was the Center for Cancer and Blood Disorders. We met with doctors, had a blood test done, and they came back with the dreaded words, "Your child has cancer." Specifically, he had acute lymphoblastic leukemia (ALL).
Lisa
I noticed some lymph nodes popped up on my neck so I went to the Dr. I didn't feel bad at all. My Dr ordered blood work and my white blood count was high. I was sent to The Cancer Center of Acadiana and more blood work, scans, ultrasound and bone biopsy was done. After all the results came in my white blood count was 99,000 and I had 75% leukemia cells in my bone marrow. I was diagnosed with CLL. 4 days later I was in the Infusion room at The Cancer Center of Acadiana. After 5 months of chemo going 2 days every month I am leukemia free.
Angela
My name is Angela, and I have myeloproliferative neoplasms (MPN), a rare blood cancer. I was diagnosed when I was 16. I had a series of blood tests done after being raped, and that began my cancer journey. I began cancer treatment even though at that time (the late 90s) my condition was known as a “blood disorder” not cancer. In my early 20s, I suffered strokes, a heart attack, and a brain hemorrhage. I survived. I struggled to get and stay pregnant and was on life support after having my daughter prematurely at 26 weeks and six days. And I survived.
Myeloma
Is a type of cancer that begins in the bone marrow. It is a cancer of plasma cells, which are a type of white blood cells (also called plasma B cells). The disease belongs to a spectrum of disorders referred to as “plasma cell dyscrasias” or "plasma cell neoplasms", and has several forms.
Mendya
First, I must express appreciation to The Leukemia & Lymphoma Society (LLS) for providing educational resources, knowledge, and financial assistance to those of us affected by blood cancer. LLS spotlights blood cancer and gives a voice to so many like myself. Thank you. As a way to show my support to LLS and to raise awareness, I have raised $210 in September 2023, Blood Cancer Awareness Month (BCAM), via Facebook. This is just the beginning of my advocacy.
Quade
Quade “Q” Marks is a 14-year-old freshman at East High School in Denver, Colorado. He loves to play lacrosse, ski, snowboard and aspires to be a trauma surgeon. He is also a blood cancer survivor.